642 related articles for article (PubMed ID: 17387725)
1. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
2. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
3. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
4. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
5. Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?
Wolsey DH; Larson SA; Creel D; Hoffman R
J AAPOS; 2006 Aug; 10(4):307-11. PubMed ID: 16935228
[TBL] [Abstract][Full Text] [Related]
6. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
[TBL] [Abstract][Full Text] [Related]
7. Optic pathway glioma of childhood.
Rasool N; Odel JG; Kazim M
Curr Opin Ophthalmol; 2017 May; 28(3):289-295. PubMed ID: 28257299
[TBL] [Abstract][Full Text] [Related]
8. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.
King A; Listernick R; Charrow J; Piersall L; Gutmann DH
Am J Med Genet A; 2003 Oct; 122A(2):95-9. PubMed ID: 12955759
[TBL] [Abstract][Full Text] [Related]
9. Optic Gliomas in Neurofibromatosis Type 1.
Parkhurst E; Abboy S
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):334-338. PubMed ID: 27537249
[TBL] [Abstract][Full Text] [Related]
10. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis 1-associated optic pathway gliomas.
Shofty B; Ben Sira L; Constantini S
Childs Nerv Syst; 2020 Oct; 36(10):2351-2361. PubMed ID: 32524182
[TBL] [Abstract][Full Text] [Related]
12. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
13. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
16. Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit.
Pilling RF; Lloyd IC; Huson S
Eye (Lond); 2010 Oct; 24(10):1603-5. PubMed ID: 20689568
[TBL] [Abstract][Full Text] [Related]
17. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
18. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
19. Neuroophthalmological management of optic pathway gliomas.
Lee AG
Neurosurg Focus; 2007; 23(5):E1. PubMed ID: 18004957
[TBL] [Abstract][Full Text] [Related]
20. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
